In this Review, Yvan-Charvet and colleagues discuss how cardiovascular risk factors and metabolic modifiers of atherosclerosis influence metabolism-dependent haematopoietic stem cell skewing (haematometabolism) and efferocyte reprogramming (efferotabolism) and highlight potential therapeutic strategies to reduce the risk of atherosclerosis by rebalancing haematopoiesis and efferocytosis.
- Laurent Yvan-Charvet
- Thibault Barouillet
- Coraline Borowczyk
